Research synthesis
Do risperidone and aripiprazole help autistic children?
What 8 sources say about irritability, aggression, and side effects — not a treatment for autism itself.
Spectrum Connect reviews published research on interventions parents are exploring for their autistic children — so you can see where the evidence actually stands. No agenda, no selling, no cherry-picking. Just the studies, our method, and what it means for you.
Key Takeaways
This isn't a treatment for autism itself — risperidone and aripiprazole are approved for severe irritability and aggression: self-injury or aggression that puts safety at risk. They don't make a child “less autistic,” and research finds no meaningful effect on core autism traits.
The evidence for irritability is genuinely strong — these are the only two medications FDA-approved for autism, backed by multiple well-run trials and systematic reviews. This is one of the better-evidenced medication findings in this research library.
Real, significant side effects — weight gain is the most consistent, often substantial, effect, along with drowsiness. Movement side effects and, with risperidone, a hormone change can also occur. These require ongoing weight and metabolic monitoring.
Most evidence is short-term — most trials ran eight weeks or less. Less is known about whether the benefit lasts, or how side effects add up, over years of use.
These are usually considered for severe irritability when other supports haven't been enough, always alongside a prescriber who monitors for side effects — this page isn't a substitute for that conversation.
What this means for you
Risperidone and aripiprazole are antipsychotic medicines — the only two the FDA has approved for use in autism, specifically for irritability and aggression (severe tantrums, self-injury, aggression), not for autism's core traits. Multiple well-run, blinded trials and the FDA's approval show both reduce severe irritability and aggression compared with a placebo, at least short-term (weeks to a few months). Reviews differ a little on exactly how certain to be, but they agree on the direction.
These medicines do not treat autism itself — research finds no meaningful effect on core social communication, and no clear effect on repetitive behaviors. And the side effects are real: weight gain (often substantial), increased appetite, and the metabolic changes that can follow are the most consistent finding, along with common drowsiness and, less often, movement side effects or a hormone change with risperidone.
Who was studied. Autistic children and teenagers, given oral risperidone or aripiprazole, mostly for eight weeks or less, measured on irritability rating scales. Much less is known about long-term use — whether the benefit lasts and how side effects add up over years.
Where the studies landed
Settled — irritability & aggressionThese 8 sources are grouped by what they found for irritability and aggression — the best-evidenced outcome. Core autism traits are covered separately below, in “What the strongest evidence says.” Tap a band to see what those studies actually said.
Points toward it helping6
Mixed — efficacy uncertain, safety unclear1
Different outcome — no effect on core autism traits1
Each tile is one source. The ringed tiles are systematic reviews or meta-analyses that pool multiple trials — the stronger kind, though most pool the same small set of pivotal trials rather than independent evidence.
See the research behind this
Search strategy, PRISMA flow & evidence strength — 8 sources
Where we looked
This run was a scoping search only — done via general web search, not the reproducible Boolean search of record and not the PubMed/Epistemonikos API layer we use on a fully conformant run. That means we can't publish reproducible per-database counts or a formal PRISMA flow for this run. Below is the search string a full conformant pass would run against PubMed, the Cochrane Library, Epistemonikos, Embase, PsycINFO, CINAHL, and ClinicalTrials.gov — we haven't executed it against the database APIs yet.
("autism spectrum disorder"[MeSH] OR autistic[tiab] OR ASD[tiab]) AND (risperidone[tiab] OR aripiprazole[tiab] OR "atypical antipsychotic*"[tiab] OR "second-generation antipsychotic*"[tiab]) AND (irritability[tiab] OR aggression[tiab] OR "Aberrant Behavior Checklist"[tiab] OR efficacy[tiab]) AND (systematic[sb] OR "meta-analysis"[pt] OR "randomized controlled trial"[pt])
Run on PubMed →
What we did with what we found
What the strongest evidence says
Multiple well-run, blinded trials — and the FDA's approval — show both medicines reduce severe irritability and aggression versus placebo, at least short-term. Reviews differ a little on exact certainty but agree on direction.
No meaningful effect on core social communication, and no clear effect on repetitive behaviors. These medicines target distress and behavior, not autism's core traits.
The most consistent and often substantial side effect is weight gain, with related metabolic changes. Drowsiness is common; movement side effects and, with risperidone, a hormone change can occur. These require ongoing weight and metabolic monitoring.
Test run — not for publication · Awaiting independent sign-off · not medical advice
We publish the whole record so it can be checked — and that only counts if we act on what you find. If a number looks wrong, a study is missing or has been retracted, or we’ve read a finding in a way the evidence doesn’t support, tell us.
You don’t need a research background to file one. “This doesn’t match what our doctor told us” is a useful report. Every one reaches a person: we reply within seven days, and within thirty we have either corrected the page or told you when we will. Substantive reports send the affected steps back through the protocol and need fresh sign-off before anything here changes.
Report a factual error